APPLICATION
ANDA210924
TYPE
ANDA
ORIGINAL APPROVAL
2020-06-19
LATEST ACTION
2020-06-19
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
MARKETING STATUS
Prescription
Products
METHYLPHENIDATEPrescription
METHYLPHENIDATE 17.3MG · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE · ORAL
METHYLPHENIDATEPrescription
METHYLPHENIDATE 25.9MG · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE · ORAL
METHYLPHENIDATEPrescription
METHYLPHENIDATE 8.6MG · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.